Last reviewed · How we verify
ACHIM
At a glance
| Generic name | ACHIM |
|---|---|
| Also known as | Anaerobic cultured human intestinal microbiota |
| Sponsor | Uppsala University |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Fecal Microbiota Transplantation and ACHIM for Manipulating Gut Microbiota in IBS Patients (NA)
- Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) (PHASE2)
- IMT for Primary Clostridium Difficile Infection (PHASE2, PHASE3)
- Gut Microbiota Transplantation in Systemic Sclerosis (PHASE1, PHASE2)
- Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile (PHASE2)
- Transplantation of Anaerobic Cultured Human Intestinal Microbiota in Irritable Bowel Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACHIM CI brief — competitive landscape report
- ACHIM updates RSS · CI watch RSS
- Uppsala University portfolio CI